Boyd C J, McDonell W N, Valliant A
Department of Clinical Studies, Ontario Veterinary College, University of Guelph.
Can J Vet Res. 1991 Apr;55(2):107-12.
The purpose of this study was to compare the cardiovascular effects of halothane when used alone at increasing doses (1.2, 1.45 and 1.7 minimum alveolar concentration, MAC) to those produced with equipotent doses of halothane after potentiation of the anesthetic effect with acepromazine (ACP) sedation (45% reduction of halothane MAC). Six healthy mature dogs were used on three occasions. The treatments were halothane and intramuscular (IM) saline (1.0 mL), halothane and ACP (0.04 mg/kg IM), or halothane and ACP (0.2 mg/kg IM). Anesthesia was induced and maintained with halothane in oxygen and the dogs were prepared for the collection of arterial and mixed venous blood and for the determination of heart rate, systolic, diastolic and mean arterial pressure, mean pulmonary arterial pressure (PAP), central venous pressure and cardiac output. Following animal preparation the saline or ACP was administered and positive pressure ventilation instituted. Twenty-five minutes later the dogs were exposed to the first of three anesthetic levels, with random assignment of the sequence of administration. At each anesthetic level, measurements were obtained at 20 and 35 min. Calculated values included cardiac index, stroke index, left ventricular work, systemic vascular resistance, arterial oxygen content, mixed venous oxygen content, oxygen delivery and oxygen consumption. Heart rate was significantly higher with halothane alone than with both halothane-ACP combinations and was significantly higher with high dose ACP compared to low dose ACP. Systolic and mean blood pressures were lowest with halothane alone and highest with 0.2 mg/kg ACP, the differences being significant for each treatment. Oxygen uptake and PAP were significantly lower in dogs treated with ACP. It was concluded that ACP does not potentiate the cardiovascular depression that accompanies halothane anesthesia when the resultant lower dose requirements of halothane are taken into consideration.
本研究的目的是比较单独使用不同剂量(1.2、1.45和1.7最低肺泡浓度,MAC)的氟烷时的心血管效应,与用乙酰丙嗪(ACP)镇静增强麻醉效果后(氟烷MAC降低45%)使用等效剂量氟烷时产生的心血管效应。六只健康成年犬分三次使用。治疗方法为氟烷和肌肉注射(IM)生理盐水(1.0 mL)、氟烷和ACP(0.04 mg/kg IM)或氟烷和ACP(0.2 mg/kg IM)。用氟烷在氧气中诱导并维持麻醉,对犬进行准备以采集动脉血和混合静脉血,并测定心率、收缩压、舒张压和平均动脉压、平均肺动脉压(PAP)、中心静脉压和心输出量。动物准备完成后,给予生理盐水或ACP并开始正压通气。25分钟后,使犬暴露于三个麻醉水平中的第一个,麻醉给药顺序随机分配。在每个麻醉水平,于20分钟和35分钟时进行测量。计算值包括心脏指数、每搏指数、左心室作功、全身血管阻力、动脉血氧含量、混合静脉血氧含量、氧输送和氧消耗。单独使用氟烷时心率显著高于两种氟烷-ACP联合用药时,且高剂量ACP组心率显著高于低剂量ACP组。单独使用氟烷时收缩压和平均血压最低,0.2 mg/kg ACP组最高,各治疗组间差异显著。接受ACP治疗的犬氧摄取和PAP显著降低。得出的结论是,当考虑到氟烷较低的剂量需求时,ACP不会增强氟烷麻醉伴随的心血管抑制作用。